Prospects for a Group A Streptococcal Vaccine: Rationale, Feasibility, and Obstacles--Report of a National Institute of Allergy and Infectious Diseases Workshop
Open Access
- 15 October 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (8), 1150-1156
- https://doi.org/10.1086/444505
Abstract
Infections due to group A streptococci (GAS) represent a public health problem of major proportions in both developing and developed countries. Currently available methods of prevention are either inadequate or ineffective, as attested to by the morbidity and mortality associated with this ubiquitous pathogen worldwide. Advances in molecular biology have shed new light on the pathogenesis of GAS infections and have identified a number of virulence factors as potential vaccine targets. Therefore, the National Institute of Allergy and Infectious Diseases convened an expert workshop in March 2004 to review the available data and to explore the microbiologic, immunologic, epidemiologic, and economic issues involved in development and implementation of a safe and effective GAS vaccine. Participants included scientists and clinicians involved in GAS research, as well as representatives of United States federal agencies (Centers for Disease Control and Prevention, Food and Drug Administration, Department of Defense, and National Institute of Allergy and Infectious Diseases), the World Health Organization, and the pharmaceutical industry. This report summarizes the deliberations of the workshop.Keywords
This publication has 36 references indexed in Scilit:
- Multivalent Group A Streptococcal Vaccine Elicits Bactericidal Antibodies against Variant M SubtypesClinical and Vaccine Immunology, 2005
- Clinical and Microbiological Responses of Volunteers to Combined Intranasal and Oral Inoculation with a Streptococcus gordonii Carrier Strain Intended for Future Use as a Group A Streptococcus VaccineInfection and Immunity, 2005
- Rheumatic Fever in Children Under 5 YearsPublished by American Academy of Pediatrics (AAP) ,2004
- Immunization with C5a Peptidase or Peptidase-Type III Polysaccharide Conjugate Vaccines Enhances Clearance of Group B Streptococci from Lungs of Infected MiceInfection and Immunity, 2002
- Toxoids of Streptococcal Pyrogenic Exotoxin A Are Protective in Rabbit Models of Streptococcal Toxic Shock SyndromeInfection and Immunity, 2000
- Variable Susceptibility to Opsonophagocytosis of Group A Streptococcus M‐1 Strains by Human Immune SeraThe Journal of Infectious Diseases, 1999
- New protective antigen of group A streptococciJCI Insight, 1999
- Protective Immune Response againstStreptococcus pyogenesin Mice after Intranasal Vaccination with the Fibronectin‐Binding Protein SfbIThe Journal of Infectious Diseases, 1999
- Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein.The Journal of Experimental Medicine, 1979
- Protective Studies with a Group A Streptococcal M Protein Vaccine. II. Challenge of Volunteers after Local Immunization in the Upper Respiratory TractThe Journal of Infectious Diseases, 1975